TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIONTECH ADR Share Price

Certificat

DE000SQ55JV4

Market Closed - Börse Stuttgart 20:50:18 24/05/2024 BST
11.15 EUR +1.55% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIONTECH ADR
Current month-7.24%
1 month-7.47%
Date Price Change
24/05/24 11.15 +1.55%
23/05/24 10.98 +2.62%
22/05/24 10.7 -7.68%
21/05/24 11.59 +0.43%
20/05/24 11.54 -0.94%

Delayed Quote Börse Stuttgart

Last update May 24, 2024 at 08:50 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying BIONTECH SE
IssuerLogo Issuer Société Générale Société Générale
WKN SQ55JV
ISINDE000SQ55JV4
Date issued 15/12/2022
Strike 216.6 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.92
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 12.4
Lowest since issue 2.89

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
89.32 EUR
Average target price
104.7 EUR
Spread / Average Target
+17.22%
Consensus